Ipratropium aeronautical
Ipratropium-aeronativ: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews Ipratropium-aeronaut
- 19. Price in pharmacies
Latin name: Ipratropium-aeronativ
ATX code: R03BB01
Active ingredient: ipratropium bromide (Ipratropium bromide)
Manufacturer: Pharmstandard-Leksredstva OJSC (Russia), Nativa LLC (Russia)
Description and photo update: 2019-08-07
Prices in pharmacies: from 242 rubles.
Buy
Ipratropium aeronautical is a bronchodilator.
Release form and composition
Dosage form - metered dose aerosol for inhalation: a transparent colorless solution, which, when leaving the container, is sprayed in the form of an aerosol stream (200 doses of the drug under pressure in stainless steel cylinders equipped with a dosing valve and a spray nozzle, one cylinder with instructions for application of Ipratropium-aeronaut is placed in a cardboard box).
Composition of 1 dose of aerosol:
- active substance: ipratropium bromide (in the form of monohydrate) - 20 μg;
- auxiliary components: triethyl citrate, citric acid monohydrate, propellant R 134a (1,1,1,2-tetrafluoroethane), ethanol (absolute ethyl alcohol).
Pharmacological properties
Pharmacodynamics
Ipratropium bromide - M-anticholinergic. The drug blocks the M-cholinergic receptors of the smooth muscles of the tracheobronchial tree (mainly at the level of medium and large bronchi) and suppresses reflex bronchoconstriction.
Structurally similar to the acetylcholine molecule, ipratropium bromide is its competitive antagonist. Effectively prevents narrowing of the bronchi under the influence of various bronchospasmodic substances, cold air, inhaled cigarette smoke. Suppresses bronchospasm caused by the influence of the vagus nerve.
When inhaled, Ipratropium-aeronaut practically does not have a resorptive property, since about 500 doses are required to be inhaled for the development of tachycardia. At the same time, only about 10% of the drug reaches the small bronchi and alveoli, the rest is deposited in the oral cavity or pharynx and is swallowed.
In case of bronchospasm associated with chronic obstructive pulmonary diseases, such as chronic bronchitis and pulmonary emphysema, the agent improves the function of external respiration, namely, increases the forced expiratory volume in the first second (FEV 1) and the maximum mean expiratory flow (FEF 25-75%) minimum by 15% within 15 minutes after inhalation. The maximum effect of the drug is achieved after 1–2 hours and usually lasts up to 6 hours.
In bronchial asthma, a significant improvement in the function of external respiration (an increase in FEV 1 by 15% or more) is observed in 40% of patients.
Pharmacokinetics
- absorption: when inhaled, ipratropium bromide is characterized by low absorption from the mucous membrane of the respiratory tract. The drug, which settles in the mouth or pharynx and is swallowed, is practically not absorbed in the gastrointestinal tract. After inhalation, the systemic bioavailability of ipratropium bromide is low (~ 7%), therefore the systemic anticholinergic effects are poorly expressed. The action develops within 5 minutes after inhalation, reaches a maximum in 30-60 minutes, lasts up to 8 hours;
- distribution: the connection with plasma proteins is 20% of the dose of the drug that has entered the systemic circulation. Ipratropium bromide is poorly soluble in fats, weakly penetrates biological membranes, does not penetrate the blood-brain barrier at all. Does not accumulate in the body;
- metabolism: ipratropium bromide is metabolized in the liver, as a result of which 8 pharmacologically inactive and weakly active metabolites with anticholinergic action are formed;
- excretion: the drug is excreted mainly through the intestines. Approximately 25% of ipratropium bromide is excreted unchanged, the rest is in the form of metabolites. Metabolites are partially excreted by the kidneys. The half-life is 3-4 hours.
Indications for use
- Chronical bronchitis;
- chronic obstructive pulmonary disease;
- bronchial asthma of mild to moderate severity, especially in patients with concomitant cardiovascular diseases;
- emphysema of the lungs.
Contraindications
Absolute:
- I trimester of pregnancy;
- hypersensitivity to any component of the drug, atropine and its derivatives.
With caution, Ipratropium Aeronautical should be used in patients with urinary tract obstruction, angle-closure glaucoma, prostatic hyperplasia, children under 6 years of age, pregnant women in the II-III trimesters and breastfeeding women.
Ipratropium aeronautical, instructions for use: method and dosage
Ipratropium Aeronaut is intended for inhalation use.
The optimal dose is selected by the doctor individually for each patient.
Adults and children over 6 years old are usually prescribed 2 inhalation doses (40 mcg) 4 times a day. The maximum permissible daily dose is 12 inhalations (240 mcg). The need to increase the dose may indicate a deterioration in disease control, which requires a revision of treatment tactics.
If Ipratropium aeronautical is not effective enough or the condition worsens, you should consult your doctor. Urgent medical advice is needed in case of sudden onset and rapid progression of shortness of breath.
Information on the use of Ipratropium Aeronautic in children under 6 years of age is limited, therefore the recommended dose is 1 inhalation (20 μg) 3 times a day. Treatment should be carried out under close medical supervision.
Directions for using the inhaler
Before using the inhaler for the first time and in case of a long break in use (7 or more days), it is necessary to check its operation: remove the protective cap from the mouthpiece, shake the inhaler well and press the balloon, releasing one dose of the drug into the air.
Inhalation rules:
- Remove the protective cap from the mouthpiece.
- Shake inhaler vigorously.
- Exhale slowly.
- Holding the balloon upside down (with your middle finger on top and your thumb on the bottom), tightly wrap your lips around the mouthpiece.
- Take as deep a breath as possible and simultaneously quickly press the bottom of the balloon to release one inhalation dose.
- Hold your breath for a few seconds. Remove the mouthpiece from your mouth and exhale slowly through your nose.
- For a second dose, if necessary, repeat steps 3-6.
- Put on the protective cap on the mouthpiece.
At least 1 time per week, the inhaler mouthpiece should be cleaned with clean warm water, after removing the metal can from the plastic case. Then dry without using heating devices, and then put the can back in the case. Do not wet or rinse the metal container.
The plastic mouthpiece is specially designed for the Ipratropium Aeronautic preparation and is used for precise dosage of the drug. It is not intended for use with other metered-dose aerosols. Also, you cannot use Ipratropium Aeronautic with any other adapters other than the supplied mouthpiece.
The aerosol in the can is under pressure. The cylinder must not be heated above 50 ° C and must not be opened.
Side effects
- from the digestive system: very often (more than 1/10) - nausea; often (from 1/100 to 1/10) - dry mouth; rarely (from 1/10 000 to 1/1000) - diarrhea, vomiting, abdominal pain;
- allergic reactions: infrequently (from 1/1000 to 1/100) - itching, urticaria, skin rash, laryngospasm, anaphylactic reactions, angioedema of the tongue, lips and face, exudative erythema multiforme, bronchospasm;
- from the respiratory system: infrequently - cough; rarely - paradoxical bronchospasm;
- from the nervous system: very often - headache;
- on the part of the organ of vision: very rarely (less than 1/10 000) - when an aerosol gets into the eyes, pain in the eye, dilated pupil (mydriasis), angle-closure glaucoma, increased intraocular pressure (especially in patients with angle-closure glaucoma) are observed. Feeling of discomfort or pain in the eye, blurred vision, the appearance of a halo and colored spots before the eyes in combination with corneal and conjunctival hyperemia can be symptoms of an attack of angle-closure glaucoma;
- effects associated with the anticholinergic action of ipratropium bromide: rarely - impaired motility of the gastrointestinal tract, constipation, decreased secretion of sweat glands, urinary retention (especially in patients with obstructive urinary tract damage), impaired accommodation, heart palpitations, supraventricular tachycardia (these effects are nasal reversible);
- others: very often - an increase in the viscosity of sputum.
Overdose
In case of overdose, no specific symptoms were recorded. Considering the local route of administration of the drug and the breadth of its therapeutic action, the development of serious anticholinergic effects is unlikely. The appearance of minor signs of the systemic anticholinergic action of Ipratropium-aeronautical, such as dry mouth, increased heart rate, and impaired accommodation, is possible.
It is shown that symptomatic therapy is carried out to eliminate the developed disorders.
special instructions
Ipratropium aeronautical is not recommended for emergency relief of an attack of bronchial asthma, since its bronchodilator effect develops longer than that of beta-adrenomimetics.
The physician must ensure that the patient knows how to use the inhaler correctly.
Patients should be warned about the need for medical advice in case of insufficient effectiveness of therapy or worsening of the condition, as well as the sudden onset and rapid progression of shortness of breath.
People with cystic fibrosis are at greater risk of gastrointestinal motility disorders.
If any symptom of an attack of angle-closure glaucoma appears (discomfort or pain in the eye, the appearance of a halo and colored spots before the eyes, blurred vision in combination with corneal and conjunctival hyperemia), it is necessary to drip drops that cause constriction of the pupil, and urgently consult an ophthalmologist.
Influence on the ability to drive vehicles and complex mechanisms
The effect of ipratropium bromide on cognitive and psychomotor functions has not been studied. Patients who have side effects from the central nervous system or the organ of vision should refrain from performing potentially hazardous activities, including driving.
Application during pregnancy and lactation
In the course of preclinical studies, no embryotoxic and teratogenic effects of ipratropium bromide, administered inhaled and intranasally, at doses significantly higher than those recommended for humans were revealed. However, during pregnancy in humans, the safety of the drug has not been studied. In this regard, in the first trimester, the appointment of Ipratropium-aeronaut is contraindicated. In the II-III trimesters, the drug can be used only in cases where the expected benefit from the forthcoming therapy for the mother is definitely higher than the potential risks to the fetus.
It has not been established whether ipratropium bromide is excreted in breast milk. Although lipid-insoluble quaternary cations are absorbed into mother's milk, it is unlikely that inhaled Ipratropium Aeronautics will have a significant effect on an infant. If it is necessary to prescribe the drug during lactation, it is recommended to assess the balance of benefits and possible risks.
Pediatric use
There are no age restrictions for the use of Ipratropium aeronautics. However, care should be taken when treating children under 6 years of age.
With impaired renal function
There are no special instructions.
For violations of liver function
There are no special instructions.
Use in the elderly
There are no special instructions.
Drug interactions
The bronchodilating effect of Ipratropium-aeronautic is potentiated by xanthine derivatives and β 2 -adrenomimetics.
With the simultaneous use of tricyclic antidepressants, antiparkinsonian drugs, quinidine, the anticholinergic effect of Ipratropium-aeronautics is enhanced.
In the case of the joint use of other anticholinergics, an additive effect is noted.
Analogs
Analogs of Ipratropium-Aeronaut are: Atrovent, Atrovent N, Bretaris Jenueir, Inkruz Ellipta, Ipratropium-Aeronativ, Ipratropium Steri-Neb, Ipratropium-Native, Ipratropium-Air, Sibri Breezhaler, Spirivev and dr. Native Tiotropium
Terms and conditions of storage
Store at a temperature not exceeding 25 ° C in a dark place out of the reach of children, away from heating appliances. Avoid freezing.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews of Ipratropium-aeronaut
There are no reviews directly about Ipratropium-aeronautic on specialized medical sites. However, preparations based on ipratropium bromide (the active substance of Ipratropium aeronautical) are quite well-known, they have long been effectively used as bronchodilators. Doctors often prescribe these drugs for bronchitis and obstructive pulmonary disease. Ipratropium bromide is well tolerated and has a rapid onset of action after inhalation.
Price for Ipratropium-aeronaut in pharmacies
The approximate price for Ipratropium aeronautical for 1 can, containing 200 doses of 20 µg each, is 280–330 rubles.
Ipratropium aeronautical: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Ipratropium aeronautic 20 μg / dose 200 doses aerosol for inhalation metered 1 pc. 242 r Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
